Filing Flows › Veracyte (VCYT) › Q2 2026 › vs Q2 2025
Veracyte (VCYT) Q2 2026 vs Q2 2025 (year over year)
Veracyte's revenue rose $20.2M (+15%) from $130M in Q2 2025 to $150M in Q2 2026. The biggest changes: Testing revenue +$23.4M (+19%); Biopharmaceutical and other revenue −$3.5M (-81%); Product revenue +$260K (+7%). Gross margin 72.2% against 69.0% (+3.2 pts).
Veracyte, Q2 2026: revenue $150M (+16% year over year), operating margin 15.3%, net earnings $25.5M, operating cash flow $45.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 72.2% | 69.0% | +3.2 pts |
| Operating margin | 15.3% | -4.0% | +19.3 pts |
| Net margin | 17.0% | -0.8% | +17.7 pts |
| Free cash flow margin | 28.6% | 24.8% | +3.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Testing revenue | $146M | $122M | $23.4M | +19% |
| Product revenue | $3.9M | $3.6M | $260K | +7% |
| Biopharmaceutical and other revenue | $802K | $4.3M | −$3.5M | -81% |
| Revenue | $150M | $130M | $20.2M | +15% |
| Gross profit | $109M | $89.8M | $18.8M | +21% |
| Cost of revenue | $41.8M | $40.4M | $1.4M | +3% |
| Other income, net | $3.5M | $6.5M | −$3.0M | -46% |
| Operating profit | $23.0M | −$5.3M | $28.2M | — |
| Operating expenses | $85.6M | $95.0M | −$9.5M | -10% |
| Pre-tax earnings | $26.5M | $1.2M | $25.3M | 21× |
| Research & development | $29.4M | $16.3M | $13.2M | +81% |
| Sales & marketing | $28.3M | $25.3M | $2.9M | +12% |
| General & admin | $27.4M | $32.3M | −$4.9M | -15% |
| Other operating costs | $421K | $21.1M | −$20.7M | -98% |
| Net earnings | $25.5M | −$980K | $26.5M | — |
| Income tax | $1.0M | $2.2M | −$1.2M | -54% |
| Depreciation & amortization | $4.8M | $5.5M | −$651K | -12% |
| Share-based compensation | $14.1M | $11.0M | $3.1M | +28% |
| Working capital & other | $1.4M | $18.1M | −$16.7M | -92% |
| Operating cash flow | $45.8M | $33.6M | $12.2M | +36% |
| Free cash flow (OCF − capex) | $43.0M | $32.3M | $10.6M | +33% |
| Capital expenditures | $2.9M | $1.3M | $1.6M | +122% |
Questions
How much did Veracyte's revenue grow year over year in Q2 2026?
Veracyte's revenue rose $20.2M (+15%) from $130M in Q2 2025 to $150M in Q2 2026.
What drove Veracyte's revenue change in Q2 2026?
Testing revenue +$23.4M (+19%); Biopharmaceutical and other revenue −$3.5M (-81%); Product revenue +$260K (+7%).